Sanofi Pasteur, the vaccines division of Sanofi, announced today the availability of Quadracel™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus; DTaP-IPV) vaccine in the United States. Quadracel is approved by the U.S. Food and Drug Administration (FDA) for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age.
“Far too many children remain undervaccinated against serious diseases like pertussis, polio and Haemophilus influenzae type b (Hib) disease,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “We are committed to helping protect more children by making vaccination as easy and convenient as possible for parents and healthcare providers. The availability of Quadracel is a step in this direction. When Quadracel is used in children who started their immunization series with Pentacel® (DTaP-IPV/Hib), it can save an extra shot and may help improve vaccination coverage for children through 6 years of age.”
A 2015 report from the Centers for Disease Control (CDC) showed an 11 percent vaccination coverage drop-off from the third to fourth dose of DTaP, and a 12 percent drop-off from the primary to full series of Haemophilus influenzae type b (Hib).
To protect infants and children from life-threatening diseases, the CDC recommends children 4 through 6 years of age receive the fifth dose of the DTaP vaccine and the fourth dose of inactivated poliovirus (IPV) vaccine.2 Quadracel vaccine provides these two vaccines in a single shot.
“Reducing the number of vaccine injections in a multi-dose series can mean more than just convenience,” said Michael J. Smith MD, MSCE, Associate Professor of Pediatrics, University of Louisville School of Medicine. “According to the CDC, it can also lead to stocking fewer vaccines – which helps facilitate process standardization – increased staff efficiency and prevention of administration errors.”